SAN - Sanofi SA - Stock Price & Dividends

Exchange: Euronext Paris • Country: France • Currency: EUR • Type: Common Stock • ISIN: FR0000120578

Vaccines, Medicines, Skincare, Diabetes, Oncology, Immunology, Cardiovascular

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France. Web URL: https://www.sanofi.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for SAN - Sanofi SA  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for SAN - Sanofi SA  - Stock Price & Dividends

SAN Stock Overview

Market Cap in USD 145,611m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception

SAN Stock Ratings

Growth 5y 55.1
Fundamental 47.9
Dividend 66.7
Rel. Performance vs Sector 1.50
Analysts -
Fair Price Momentum 106.15 EUR
Fair Price DCF 84.29 EUR

SAN Dividends

Dividend Yield 12m 3.60%
Yield on Cost 5y 5.74%
Dividends CAGR 5y 3.01%
Payout Consistency 99.8%

SAN Growth Ratios

Growth 12m 6.31%
Growth Correlation 12m 30%
Growth Correlation 3m 97%
CAGR 5y 9.59%
CAGR/Mean DD 5y 1.18
Sharpe Ratio 12m 0.05
Alpha vs SP500 12m -6.27
Beta vs SP500 5y weekly 0.42
ValueRay RSI 93.83
Volatility GJR Garch 1y 19.89%
Price / SMA 50 8.47%
Price / SMA 200 17.39%
Current Volume 2070.9k
Average Volume 20d 1330.5k

External Links for SAN Stock

Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of SAN stocks?
As of September 08, 2024, the stock is trading at EUR 104.54 with a total of 2,070,863 shares traded.
Over the past week, the price has changed by +3.30%, over one month by +11.96%, over three months by +14.87% and over the past year by +5.91%.
What are the forecast for SAN stock price target?
According to ValueRays Forecast Model, SAN Sanofi SA will be worth about 115.4 in September 2025. The stock is currently trading at 104.54. This means that the stock has a potential upside of +10.36%.
Issuer Forecast Upside
Wallstreet Target Price 106.9 2.26
Analysts Target Price - -
ValueRay Target Price 115.4 10.4

The Evolution and Market Position of Sanofi SA

History of Sanofi SA

Sanofi SA, a global leader in healthcare, began its journey in 1973 through the merger of two French companies. Over the decades, it evolved through strategic acquisitions, innovation, and expansion to become a powerhouse in the pharmaceutical industry. Its commitment to health and well-being has made it a trusted name across the globe.

Core Business

At the heart of Sanofi's operations is its dedication to pharmaceuticals, specifically focusing on vaccines, rare diseases, multiple sclerosis, oncology, and immunology. The company's innovative approach has led to the development of numerous flagship products that address critical health issues, contributing to its reputation as a leader in the pharmaceutical sector.

Side Business Ventures

Beyond its primary focus, Sanofi has diversified interests, including consumer healthcare products, over-the-counter (OTC) medications, and animal health through its now-independent entity, Sanofi Pasteur. This expansion allows Sanofi to impact health and wellness in broader terms, reaching beyond prescription medications to everyday health solutions.

Current Market Status

As of the latest analysis, Sanofi SA stands strong in the global pharmaceutical industry. It continues to invest in research and development, ensuring a steady pipeline of innovative treatments. Despite the competitive nature of the pharmaceutical sector, Sanofi's strategic acquisitions and focus on high-growth areas have positioned it for sustained growth and profitability in the years to come.